BioLine Rx Doses First Patient in GLIX1 GBM Trial, Reports $2.5M Q1 R&D Expense
BLRX•BioLine Rx dosed first patient in its Phase 1/2a GLIX1 glioblastoma trial and secured two ASCO abstracts, while R&D expenses rose to $2.5m in Q1 from $1.6m on GLIX1 development. Q1 APHEXDA sales jumped to $2.5m from $1.4m and cash at $17.4m funds operations into H1 2027.
1. GLIX1 Phase 1/2a Trial Initiation
BioLine Rx has begun dosing in its Phase 1/2a GLIX1 trial for glioblastoma with the first patient enrolled at NYU Langone Health. Two abstracts featuring GLIX1 were accepted for presentation at the upcoming ASCO meeting, highlighting the molecule’s novel mechanism.
2. Q1 Financials: R&D and Cash Position
Research and development expenses increased to $2.5 million in Q1 2026 from $1.6 million a year earlier, driven primarily by GLIX1 project costs. The company ended the quarter with $17.4 million in cash, estimated to fund operations into the first half of 2027.
3. APHEXDA Commercial Performance
Sales of APHEXDA rose to $2.5 million in Q1 2026, up from $1.4 million in Q1 2025, reflecting growing market uptake. Management cited expanded engagement with the oncology community as a key driver of this revenue momentum.
4. Competitive Landscape and Pipeline Milestones
BioLine Rx faces limited competition in glioblastoma patient recruitment and is monitoring new pancreatic cancer data from Revolution Medicine for its CheMo4METPANC trial, with an interim futility analysis expected later this year. Specific dose levels for GLIX1 have not been disclosed, and additional trial sites at Northwestern and Moffitt will open shortly.
